CHThe article reports on the strong growth of Lonza, a pharmaceutical supplier based in Switzerland, highlighting its improved profitability and expansion efforts. Lonza has shifted focus from chemicals to pharmaceuticals and biotechnology, leading to higher margins. It gained significant revenue during the pandemic by supplying active ingredients for Moderna’s vaccines, though this contract ended in 2023. Lonza has since diversified into biologics, which now account for nearly half of its sales. The company continues to expand production capacity, particularly at its Visp site, where employment has increased beyond pandemic levels. However, the rapid growth has led to challenges such as labor shortages and local infrastructure strain. Lonza plans further investments in Switzerland, including new facilities in Stein.
Bias read (Center): The article presents factual economic developments related to Lonza's performance and strategic decisions without overtly favoring any political ideology. While it discusses the impact of global health events (like the pandemic) on corporate strategy, it does not frame these events through a politic
